Methods of administering anti-tnf.alpha. antibodies
CA 2868614 A1 · Owner: Abbott Laboratories (Bermuda) Ltd. · Inventors: Fischkoff, Steven; Weiss, Roberta; Kempeni, Joachim
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Methods of treating disorders in which TFN.alpha. activity is detrimental via biweekly, subcutaneous , administration of human antibodies preferably recombinant human antibodies that specifically , bind to human tumor necrosis factor a (hTNF.alpha.) are disclosed. The antibody may be administered , with or without methotrexate. These antibodies have high affinity for hTNF.alpha. (e.g. Kd = 10-8 M , or less) a slow off rate for hTNF.alpha. dissociation (e.g. Koff = 10-3 sec- 1 or less) and neutralize , hTNF.alpha. activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or , an antigen-binding portion thereof. Kits containing a pharmaceutical composition …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 10, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 10, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 10, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.